Cleaved-COL3A1 (G1221) Antibody

What is the Cleaved-COL3A1 (G1221) Antibody and what epitope does it recognize?

Cleaved-COL3A1 (G1221) Antibody is a rabbit polyclonal antibody that specifically detects endogenous levels of the fragment of activated COL3A1 protein resulting from cleavage adjacent to glycine at position 1221 (G1221). The antibody binds to the human Collagen III alpha1 at the amino acid region 1140-1220 C-Term, recognizing the cleaved form of the protein after proteolytic processing . This specificity is critical for researchers studying collagen processing, as it allows for the detection of specifically cleaved fragments rather than the intact protein.

What is COL3A1 and its biological significance?

COL3A1 encodes the alpha-1 chain of type III collagen, a fibrillar collagen found in extensible connective tissues such as skin, blood vessels, and internal organs. It plays crucial roles in:

• Providing structural support and elasticity to tissues

• Wound healing and tissue repair processes

• Maintaining vascular integrity

• Interacting with other extracellular matrix components such as fibronectin and elastin

Mutations in the COL3A1 gene are associated with Vascular Ehlers-Danlos syndrome (vEDS), a severe inherited disorder characterized by arterial, intestinal, and uterine fragility and ruptures .

What applications is the Cleaved-COL3A1 (G1221) Antibody validated for?

Based on the search results, the antibody has been validated for:

• Western Blot (WB): Recommended dilution ranges from 1:500-1:2000

• Enzyme-Linked Immunosorbent Assay (ELISA): Recommended dilution of 1:10000

Other COL3A1 antibodies (not specifically the cleaved form) have additional applications including:

• Immunohistochemistry (IHC)

• Flow Cytometry

• Immunofluorescence (IF)

How should I optimize Western blot conditions for detecting Cleaved-COL3A1 (G1221)?

For optimal Western blot results when using Cleaved-COL3A1 (G1221) Antibody:

• Sample preparation:

  • Use 30 μg of protein per lane

  • Include positive controls such as A549 cells treated with etoposide (25 μM for 24h)

• Gel electrophoresis:

  • Use 5-20% SDS-PAGE gradient gels due to the high molecular weight of collagen fragments

  • Run at 70V (stacking gel)/90V (resolving gel) for 2-3 hours

• Protein transfer:

  • Transfer to nitrocellulose membrane at 150 mA for 50-90 minutes

  • Use special transfer conditions for high molecular weight proteins

• Blocking:

  • Block with 5% non-fat milk in TBS for 1.5 hours at room temperature

• Primary antibody incubation:

  • Dilute at 1:500-1:2000 in blocking buffer

  • Incubate overnight at 4°C

• Washing and secondary antibody:

  • Wash with TBS-0.1% Tween, 3 times, 5 minutes each

  • Use anti-rabbit IgG-HRP at 1:5000 dilution for 1.5 hours at room temperature

• Detection:

  • Develop using Enhanced Chemiluminescent detection (ECL) kit

What is the expected band size for Cleaved-COL3A1 (G1221) and why might it differ from predicted molecular weight?

• Post-translational modifications, particularly hydroxylation and glycosylation of proline and lysine residues

• The triple helical structure of collagen

• The cleaved fragment detected by this specific antibody represents a specific portion of the protein

When observing cleaved fragments, various molecular weights may be detected depending on the specific proteolytic processing of the protein in different conditions or disease states .

What are appropriate positive and negative controls for validating Cleaved-COL3A1 (G1221) Antibody specificity?

Positive controls:

• A549 cells treated with etoposide (25μM for 24h), which induces collagen cleavage

• Tissue samples with high collagen expression such as skin or vascular tissue

Negative controls:

• Blocking with the synthesized peptide used as immunogen (available as Neutralizing Peptide)

• Non-transfected cell lines with low COL3A1 expression as comparison to transfected lines

• Primary antibody omission

• Isotype control (rabbit IgG at equivalent concentration)

How can I distinguish between intact and cleaved forms of COL3A1 in my experiments?

To differentiate between intact and cleaved COL3A1:

• Use multiple antibodies:

  • Pair the Cleaved-COL3A1 (G1221) Antibody with antibodies targeting other domains

  • Compare with antibodies recognizing the intact protein (such as those in search results , , and )

• Size comparison:

  • The cleaved fragment will appear at a different molecular weight than intact COL3A1

  • Run positive controls with known cleavage patterns

• Sequential immunoprecipitation:

  • First immunoprecipitate with an antibody against the intact protein

  • Then analyze the precipitate with the Cleaved-COL3A1 (G1221) Antibody

• 2D gel electrophoresis:

  • Separate proteins by both isoelectric point and molecular weight

  • Cleaved fragments will show distinct migration patterns

What proteases are known to cleave COL3A1 at or near the G1221 position, and how can I study this process?

While the search results don't explicitly mention which proteases cleave COL3A1 at G1221, several proteases are known to process collagens:

• Matrix metalloproteinases (MMPs): Particularly MMP-1, MMP-8, and MMP-13

• ADAMTS family proteases

• Cathepsins

To study this process:

• In vitro digestion assays:

  • Incubate purified COL3A1 with purified proteases

  • Analyze cleavage products using the Cleaved-COL3A1 (G1221) Antibody

• Protease inhibitor studies:

  • Treat cells with specific protease inhibitors

  • Monitor changes in cleaved COL3A1 detection

• Site-directed mutagenesis:

  • Introduce mutations at the G1221 site

  • Assess impact on cleavage susceptibility

How can I incorporate Cleaved-COL3A1 (G1221) Antibody detection in studies of Ehlers-Danlos syndrome?

The COL3A1 gene is particularly important in vascular Ehlers-Danlos syndrome (vEDS). The Cleaved-COL3A1 (G1221) Antibody could be valuable in:

• Comparing cleavage patterns:

  • Analyze tissue or serum samples from vEDS patients versus controls

  • Investigate whether specific mutations alter cleavage patterns

• Mechanistic studies:

  • Examine how different COL3A1 mutations (glycine substitutions, splice-site variants, haploinsufficiency) affect protein processing

  • The search results indicate different mutation types have varying clinical consequences

• Biomarker development:

  • Evaluate whether cleaved fragments can serve as diagnostic or prognostic biomarkers

  • Correlate levels of cleaved fragments with disease severity

Data compiled from search result

How does the Cleaved-COL3A1 (G1221) Antibody compare with other COL3A1 antibodies?

The Cleaved-COL3A1 (G1221) Antibody differs from other COL3A1 antibodies in several key aspects:

• Epitope specificity:

  • Recognizes specifically the cleaved form at G1221

  • Other antibodies (search results , , ) recognize different epitopes of the intact protein

• Applications:

  • Primarily validated for WB and ELISA

  • Other COL3A1 antibodies have broader application ranges including IHC, IF, and flow cytometry

• Species reactivity:

  • Cleaved-COL3A1 (G1221) Antibody: Human, Rat, Mouse

  • Other antibodies may have additional reactivity with species like porcine and bovine

This specialization makes the Cleaved-COL3A1 (G1221) Antibody particularly valuable for studies focused on protein processing rather than general expression analysis.

What species cross-reactivity has been validated for this antibody?

According to the search results, the Cleaved-COL3A1 (G1221) Antibody has been validated for:

Experimentally confirmed reactivity:

• Human

• Rat

• Mouse

Other COL3A1 antibodies (not specifically the cleaved form) have additional predicted reactivity with:

• Bovine (94% homology)

• Rhesus Macaque (98% homology)

• Porcine (reported in literature)

• Chicken (83% homology)

• Xenopus laevis (80% homology)

When using this antibody with non-validated species, researchers should perform their own validation experiments.

How can I use the Cleaved-COL3A1 (G1221) Antibody to study the relationship between collagen processing and fibrosis?

Type III collagen is implicated in various fibrotic conditions. The Cleaved-COL3A1 (G1221) Antibody can be used to:

• Compare processing patterns:

  • Analyze cleaved versus intact collagen ratios in normal versus fibrotic tissues

  • Determine if alterations in collagen processing precede fibrosis development

• Intervention studies:

  • Monitor changes in cleaved collagen levels after anti-fibrotic treatments

  • Assess whether preventing specific cleavage events affects fibrosis progression

• Cell type-specific analysis:

  • Use dual immunofluorescence with cell-type markers to identify which cells produce cleaved collagen

  • Determine if different cell populations process collagen differently in fibrotic conditions

The search results note that "several types of fibroses [are] associated with type III collagen... in which increased amounts of type III collagen accumulate in the target organs" .

What are the best sample preparation techniques for detecting Cleaved-COL3A1 in different tissue types?

Optimal sample preparation varies depending on tissue type and experimental goal:

• For Western blot analysis:

  • Tissues rich in extracellular matrix (skin, blood vessels): Use stronger lysis buffers containing higher detergent concentrations

  • Include protease inhibitors to prevent artifactual cleavage during processing

  • Consider using sequential extraction methods to fully solubilize collagen

• For immunohistochemistry:

  • Paraffin-embedded sections: Use antigen retrieval with Trilogy™ (EDTA-based, pH 8.0) buffer for 15 minutes

  • Frozen sections: Fix briefly with paraformaldehyde to preserve tissue morphology

  • For vascular tissues, orientation is important to differentiate between different vessel layers

• For flow cytometry (if adapting protocols from other COL3A1 antibodies):

  • Fix cells with 4% paraformaldehyde

  • Block with 10% normal goat serum

  • Permeabilize to detect intracellular collagen

How should I interpret differences in Cleaved-COL3A1 detection between normal and pathological samples?

When comparing normal and pathological samples:

• Consider both quantity and distribution:

  • Increased cleaved fragments may indicate enhanced degradation or abnormal processing

  • Altered localization may suggest disrupted extracellular matrix organization

• Analyze in context of other collagen forms:

  • Compare with levels of intact COL3A1

  • Calculate ratios of cleaved to intact protein as a measure of processing

• Account for cell/tissue variability:

  • Different tissues have varying baseline levels of COL3A1 expression

  • Control for total protein and use appropriate normalization

• Consider disease-specific changes:

  • In vascular Ehlers-Danlos syndrome: Examine how different mutation types affect cleavage patterns

  • In fibrosis: Assess whether aberrant cleavage contributes to pathological collagen accumulation

What are the common technical challenges when working with the Cleaved-COL3A1 (G1221) Antibody and how can they be addressed?

Researchers may encounter several challenges:

• High molecular weight detection issues:

  • Problem: Collagen fragments may be difficult to transfer or resolve

  • Solution: Use gradient gels (5-20% SDS-PAGE) and extend transfer times

• Non-specific bands:

  • Problem: Multiple bands may appear on Western blots

  • Solution: Include the neutralizing peptide as a blocking control

  • Solution: Optimize antibody dilution and incubation conditions

• Sensitivity limitations:

  • Problem: Low levels of cleaved fragments may be difficult to detect

  • Solution: Consider using enhanced chemiluminescence detection systems

  • Solution: Increase protein loading (up to 30μg has been validated)

• Reproducibility concerns:

  • Problem: Variability between experiments

  • Solution: Standardize sample processing, especially timing after collection

  • Solution: Include positive controls in every experiment

How might the Cleaved-COL3A1 (G1221) Antibody be used to investigate the relationship between collagen processing and vascular dysfunction?

Type III collagen is essential for vascular integrity, and its processing may be critical in vascular pathologies:

• Mechanistic studies:

  • Investigate whether specific cleavage events at G1221 precede vascular fragility

  • Determine if cleaved fragments have signaling roles distinct from intact protein

• Comparative analyses:

  • Examine differences in collagen processing between:

    • Different vascular beds (elastic vs. muscular arteries)

    • Vessels from patients with different COL3A1 mutations

• Intervention potential:

  • Test whether preventing specific cleavage events protects against vascular fragility

  • Explore if cleaved fragments could serve as biomarkers for vascular risk in vEDS patients

The search results indicate that different types of COL3A1 mutations have varying effects on vascular complications: "aortic complications (aneurysms, dissections and ruptures) appear to be more prevalent in patients with haplo-insufficiency (4/8, 50% of index cases), when compared with glycine substitution (19/79, 19%) or splice-site variant (6/45, 13%) patients" .

What role might COL3A1 processing play in brain development and neurological disorders?

The search results mention that "COL3A1 is essential for the normal brain development" , suggesting research possibilities:

• Developmental studies:

  • Track cleaved versus intact collagen patterns during brain development

  • Investigate whether specific cleavage events correlate with neuronal migration or connectivity

• Pathological investigations:

  • Examine collagen processing in brain samples from patients with "severe brain anomalies" associated with COL3A1 mutations

  • Compare with animal models of COL3A1 deficiency

• Blood-brain barrier studies:

  • Assess the role of COL3A1 and its cleaved fragments in maintaining blood-brain barrier integrity

  • Investigate the structural contribution of type III collagen to cerebral vasculature

This represents an emerging area of research that is not fully explored in the provided search results but suggests important directions for future investigation.